Literature DB >> 18083920

Nephroblastoma overexpressed (Nov) is a novel bone morphogenetic protein antagonist.

Ernesto Canalis1.   

Abstract

Nephroblastoma overexpressed (Nov), a member of the CCN family of proteins, is expressed by osteoblasts and its transcription is regulated by transforming growth factor (TGF)-beta and bone morphogenetic proteins (BMP). CCN proteins can interact with TGF-beta, BMPs, and Wnt. We explored the function of Nov in skeletal cells, in vitro and in vivo. Constitutive overexpression of Nov in cells of the osteoblastic lineage impaired osteoblastic differentiation, opposed the biological effects of BMP-2 and Wnt 3 and impaired BMP-2 and Wnt signaling, indicating that Nov has BMP-2 antagonistic activity. Transgenic mice overexpressing Nov under the control of the osteocalcin promoter exhibited osteopenia secondary to decreased bone formation, confirming the effects in vitro. GST pulldown experiments demonstrated direct Nov-BMP interactions. In conclusion, Nov has BMP antagonistic properties and inhibits osteoblastogenesis and osteoblastic function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083920     DOI: 10.1196/annals.1402.055

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.

Authors:  Véronique Ouellet; Kerstin Tiedemann; Anna Mourskaia; Jenna E Fong; Danh Tran-Thanh; Eitan Amir; Mark Clemons; Bernard Perbal; Svetlana V Komarova; Peter M Siegel
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes.

Authors:  Núria Comes; Teresa Borrás
Journal:  Physiol Genomics       Date:  2009-04-28       Impact factor: 3.107

3.  Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family.

Authors:  Tarek Abd El Kader; Satoshi Kubota; Danilo Janune; Takashi Nishida; Takako Hattori; Eriko Aoyama; Bernard Perbal; Takuo Kuboki; Masaharu Takigawa
Journal:  J Cell Commun Signal       Date:  2012-10-14       Impact factor: 5.782

4.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  The CCN family of genes: a perspective on CCN biology and therapeutic potential.

Authors:  Herman Yeger; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2008-06-21       Impact factor: 5.782

Review 6.  Structural perspective of BMP ligands and signaling.

Authors:  Gregory R Gipson; Erich J Goebel; Kaitlin N Hart; Emily C Kappes; Chandramohan Kattamuri; Jason C McCoy; Thomas B Thompson
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

7.  CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.

Authors:  Véronique Ouellet; Peter M Siegel
Journal:  J Cell Commun Signal       Date:  2012-03-18       Impact factor: 5.782

8.  Normal growth and development in mice over-expressing the CCN family member WISP3.

Authors:  Yukio Nakamura; Yajun Cui; Carol Fernando; Wendy E Kutz; Matthew L Warman
Journal:  J Cell Commun Signal       Date:  2009-04-29       Impact factor: 5.782

Review 9.  Cellular communication network factor 3 in cartilage development and maintenance.

Authors:  Satoshi Kubota; Harumi Kawaki; Bernard Perbal; Kazumi Kawata; Takako Hattori; Takashi Nishida
Journal:  J Cell Commun Signal       Date:  2021-06-14       Impact factor: 5.782

Review 10.  The CCN family proteins: modulators of bone development and novel targets in bone-associated tumors.

Authors:  Po-Chun Chen; Hsu-Chen Cheng; Shun-Fa Yang; Chiao-Wen Lin; Chih-Hsin Tang
Journal:  Biomed Res Int       Date:  2014-01-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.